Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetaminophen Mercapturate SCHEMBL30547299 | 1.00 | POLB (0.42) | POLBKDM4EUSP2EGFRLCK | |
| Acetaminophen Mercapturate SCHEMBL29048126 | 1.00 | POLB (0.42) | POLBKDM4EUSP2EGFRLCK | |
| SCHEMBL27075586 | 0.83 | PRNP (0.48) | POLBKDM4EPKMGAASMN1; SMN2 | |
| SCHEMBL10925710 | 0.80 | PTGS1 (0.52) | PTGS1 | |
| SCHEMBL31065560 | 0.79 | GAA (0.60) | POLBUSP2HSD17B10TDP1GAA | |
| SCHEMBL14003929 | 0.79 | KIF11 (0.46) | POLBKDM4EUSP2EGFRLCK | |
| SCHEMBL14003924 | 0.79 | KIF11 (0.46) | POLBKDM4EUSP2EGFRLCK | |
| SCHEMBL17164719 | 0.76 | CASR (0.41) | POLBKDM4EUSP2EGFRLCK | |
| SCHEMBL29831751 | 0.76 | POLB (0.39) | POLBKDM4EPKMGAASMN1; SMN2 | |
| SCHEMBL5024800 | 0.74 | USP2 (0.54) | POLBKDM4EUSP2EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | claimed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | claimed |
| EP-4515242-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN Pharmaceutica NV (BE) | 2025-03-05 | — | — | EP | claimed |
| CN-117665155-A | Gastric cancer blood metabolism biomarker and screening method | 浙江省肿瘤医院 | 2024-03-08 | — | — | CN | claimed |
| WO-2023209218-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-02 | — | — | WO | claimed |
| CN-116546981-A | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof and at least one thymol and/or carvacrol | 雀巢产品有限公司 | 2023-08-04 | — | — | CN | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| EP-3227681-A2 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | Bioventures, LLC (US) | 2017-10-11 | — | — | EP | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2016090163-A2 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-06-09 | — | — | WO | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2010124269-A1 | METHODS FOR DIAGNOSIS OF SEPSIS AND RISK OF DEATH | NATIONAL CENTER FOR GENOME RESOURCES (US) | 2010-10-28 | — | — | WO | claimed |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | disclosed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | disclosed |
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| US-5939535-A | Acetaldehyde and malondialdehyde protein adducts | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1997015599-A1 | NOVEL ACETALDEHYDE AND MALONDIALDEHYDE PROTEIN ADDUCTS AS MARKERS FOR ALCOHOL LIVER DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-05-01 | — | — | WO | disclosed |
| US-5474757-A | Administering diallyl sulfone to prevent metabolism of acetaminophen into hepatotoxic metabolites | RUTGERS UNIVERSITY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1994008628-A1 | PREVENTION OF ACETAMINOPHEN OVERDOSE TOXICITY WITH ORGANOSULFUR COMPOUNDS | RUTGERS UNIVERSITY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | LIPC, GGT1, TGM2 | POLB 1613/4885KDM4E 4438/4885USP2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.